FOX04-DRI 10 MG

FOX04-DRI is a synthetic peptide derivative designed as a D-retro-inverso (DRI) analog of the FOXO4 transcription factor domain. It has been developed as a stabilized research peptide primarily studied in laboratory settings for its potential effects on cellular senescence, apoptosis, and peptide pharmacology. Preclinical studies have investigated FOX04-DRI in relation to experimental models of senescent cell clearance, cancer biology, and aging.

Research involving FOX04-DRI commonly explores:

• Its role in selectively disrupting the interaction between FOXO4 and p53 to induce apoptosis in senescent cells in cellular and animal models.
• Possible contributions to reducing senescent cell burden and improving tissue function in aging-related research systems.
• Experimental evaluation of its effects on tumor growth suppression and modulation of cellular survival pathways.
• Its activity in studies of senolytic therapies, cancer treatment, and age-associated disease models, where its peptide structure and stability are key topics of interest.
FOX04-DRI is provided as a lyophilized powder for laboratory research use only (RUO). It is not intended for diagnostic, therapeutic, or clinical applications and must not be used in humans or animals.

Product details:

• Synonyms: FOXO4-DRI peptide, FOXO4 D-retro-inverso analog
• Purity: ≥98%
• CAS Number: not registered or unavailable
• Molecular Formula: not available
• Molecular Weight: not available
• Appearance: White to off-white lyophilized powder
This product is intended exclusively for scientific research and laboratory investigation in compliance with applicable regulatory guidelines.